文献速递心外重症与机械循环支持

HeartMate 3左心室辅助装置感染对心脏移植后结局的影响

Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.
PubMed 文献 · J Heart Lung Transplant · 2025-11-13

本研究回顾性分析了杜克大学医院2014至2024年间115例植入HeartMate 3后接受心脏移植的成人患者,其中51%存在移植前LVAD特异性感染。结果显示移植前LVAD特异性感染与移植后1年生存率、住院时间、急性排斥反应及严重原发性移植物功能障碍均无显著差异,提示对经仔细筛选的患者心脏移植是安全选择。

要点

  • 移植前HM3 LVAD特异性感染不增加移植后1年死亡风险(p=0.14)。
  • 移植前感染与移植后住院时间、急性排斥、严重PGD无显著关联。
  • 经仔细筛选的HM3感染患者可安全接受心脏移植。

核心结论

  • 对于经仔细筛选的HM3 LVAD特异性感染患者,心脏移植似乎是安全选择,不增加短期发病或死亡。

研究设计与样本

  • 回顾性队列研究,纳入杜克大学医院2014年1月1日至2024年12月31日期间 listed for HT 的成人患者(n=1267),其中115例植入HM3后接受心脏移植。

主要发现

  • 115例中59例(51%)移植前存在HM3 LVAD特异性感染。
  • 移植前感染组与非感染组1年移植后生存率无差异(p=0.14)。
  • 移植后住院时间(p=0.435)、治疗的急性排斥反应(p=0.536)及严重原发性移植物功能障碍(p=0.166)均无显著差异。

临床怎么用

  • 对合并HM3 LVAD特异性感染的候选者,经仔细筛选后心脏移植不因感染而禁忌。

局限性

  • 回顾性单中心设计,样本量有限,结果需外推验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infectious complications are common in patients implanted with HeartMate 3 (HM3) left ventricular assist devices (LVAD). Despite these issues, some patients with LVAD-specific infection are ultimately considered for heart transplant (HT). The impact of HM3 LVAD-associated infection on postHT outcomes remains unclear. METHODS: We reviewed all adult patients who were listed for HT at Duke University Hospital between 1/1/2014 and 12/31/2024 (n = 1267) and identified 115 patients with a HM3 device who underwent HT. These 115 patients were further stratified based on pre-HT LVAD-specific infection. We assessed the impact of LVAD-specific infection on short-term postHT complications, including length of hospitalization, primary graft dysfunction (PGD), episodes of acute rejection, and occurrences of postHT hospitalization with infection up to 1-year. Kaplan-Meier analysis was used to assess risk of death after HT. RESULTS: Of the 115 patients, 59 patients (51%) had HM3 LVAD-specific infection prior to HT. Compared to patients without pre-HT LVAD-specific infection, there was no difference in 1 year post-HT survival (p = 0.14). Similarly, there was no difference in postHT length of stay (p = 0.435), treated acute rejection (p = 0.536), or severe PGD (p = 0.166). CONCLUSIONS: For carefully selected patients with HM3 LVAD-specific infections, HT appears to be a safe option without excess short-term morbidity or mortality HT.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Rushakoff JA, Tam PCK, Kothadia SM, et al. Impact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant. J Heart Lung Transplant. 2025. PMID: 41241030. doi:10.1016/j.healun.2025.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。